<p>Respiratory diseases cause the majority of deaths and disabilities in both developed and emerging countries. The global burden of acute and chronic pulmonary diseases is rising, posing a significant challenge to public health systems. Acute lung conditions include pneumonia, influenza, and other viral infections, while chronic respiratory diseases involve chronic obstructive pulmonary disease (COPD), asthma, tuberculosis, cystic fibrosis (CF), and lung cancer. Specifically, chronic pulmonary diseases are incurable, and treating acute conditions is complex. Recent advances in nanotechnology have introduced nanocarriers, such as Pluronic F127 and PEG-based micelles, which have shown remarkable effectiveness in increasing bioavailability, enhancing mucus adhesion and penetration, and enabling sustained drug release. Promising results have been reported with formulations such as insulin-loaded micelles, which exhibit superior aerosolization, and curcumin nanocrystals in microparticles, facilitating efficient drug dissolution and retention. Furthermore, the review discusses how mucus-penetrating nanocarriers interact with mucus, the challenges involved in developing nanoparticles, and their potential clinical applications. Additionally, integrating artificial intelligence (AI) approaches could revolutionize lung disease treatment and improve patient outcomes. Alongside these advancements, pH-responsive nanotherapeutics offer targeted strategies tailored to the acidic microenvironment of diseased lung tissues. This review provides a concise overview of recent developments in pulmonary drug delivery systems and advanced nanotherapeutics, emphasizing their potential to transform treatment approaches for both acute and chronic lung diseases. Future research and ongoing clinical trials in this field will address the following issues.</p>